Urinary Angiotensin-Converting Enzyme 2 in Hypertensive Patients May Be Increased by Olmesartan, an Angiotensin II Receptor Blocker
Top Cited Papers
Open Access
- 18 May 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 28 (1), 15-21
- https://doi.org/10.1093/ajh/hpu086
Abstract
Angiotensin-converting enzyme 2 (ACE2) is highly expressed in the kidney and converts angiotensin (Ang) II to Ang-(1–7), a renoprotective peptide. Urinary ACE2 has been shown to be elevated in patients with chronic kidney disease. However, the effects of antihypertensive agents on urinary ACE2 remain unclear. Of participants in the Tanno-Sobetsu cohort study in 2011 (n = 617), subjects on no medication (n = 101) and hypertensive patients treated with antihypertensive agents, including the calcium channel blockers amlodipine and long-acting nifedipine; the ACE inhibitor enalapril; and the Ang II receptor blockers losartan, candesartan, valsartan, telmisartan, and olmesartan, for more than 1 year (n = 100) were enrolled, and urinary ACE2 level was measured. Glucose and hemoglobin A1c were significantly higher in patients treated with enalapril, telmisartan or olmesartan than in the control subjects. Urinary albumin-to-creatinine ratio (UACR) was significantly higher in patients treated with enalapril than in the control subjects. Urinary ACE2 level was higher in the olmesartan-treated group, but not the other treatment groups, than in the control group. Urinary ACE2 level was positively correlated with systolic blood pressure (r = 0.211; P = 0.003), UACR (r = 0.367; P < 0.001), and estimated salt intake (r = 0.260; P < 0.001). Multivariable regression analysis after adjustment of age, sex, and the correlated indices showed that the use of olmesartan was an independent predictor of urinary ACE2 level. In contrast with other antihypertensive drugs, olmesartan may uniquely increase urinary ACE2 level, which could potentially offer additional renoprotective effects.Keywords
This publication has 40 references indexed in Scilit:
- Angiotensin-converting enzyme 2: implications for blood pressure and kidney diseaseCurrent Opinion in Nephrology and Hypertension, 2009
- Loss of Angiotensin-Converting Enzyme-2 (Ace2) Accelerates Diabetic Kidney InjuryThe American Journal of Pathology, 2007
- Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin IIAmerican Journal of Physiology-Renal Physiology, 2007
- Loss of Angiotensin-Converting Enzyme-2 Leads to the Late Development of Angiotensin II-Dependent GlomerulosclerosisThe American Journal of Pathology, 2006
- The role of angiotensin converting enzyme 2 in the generation of angiotensin 1–7 by rat proximal tubulesAmerican Journal of Physiology-Renal Physiology, 2005
- Increased ACE 2 and Decreased ACE Protein in Renal Tubules From Diabetic MiceHypertension, 2004
- Angiotensin-converting enzyme 2 is an essential regulator of heart functionNature, 2002
- The angiotensin–converting enzyme gene family: genomics and pharmacologyTrends in Pharmacological Sciences, 2002
- A Human Homolog of Angiotensin-converting EnzymeJournal of Biological Chemistry, 2000
- A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9Circulation Research, 2000